{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:12:09Z","timestamp":1784409129315,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1053\/j.ackd.2010.05.007","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T09:08:46Z","timestamp":1282208926000},"page":"392-403","source":"Crossref","is-referenced-by-count":32,"title":["Antibiotic Pharmacokinetic and Pharmacodynamic Considerations in Patients With Kidney Disease"],"prefix":"10.1053","volume":"17","author":[{"given":"Rachel F.","family":"Eyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2010.05.007_bib1","unstructured":"United States Renal Data System: United States Renal Data System USRDS 2009 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009"},{"key":"10.1053\/j.ackd.2010.05.007_bib2","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2146\/090087d","article-title":"Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies","volume":"66","author":"Owens","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.ackd.2010.05.007_bib3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0891-5520(03)00057-6","article-title":"Pharmacodynamics and dosing of aminoglycosides","volume":"17","author":"Turnidge","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1053\/j.ackd.2010.05.007_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/514620","article-title":"The pharmacodynamics of aminoglycosides","volume":"27","author":"Lacy","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijantimicag.2008.09.001","article-title":"Do we still need the aminoglycosides?","volume":"33","author":"Durante-Mangoni","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1053\/j.ackd.2010.05.007_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2125.1999.00938.x","article-title":"Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily","volume":"47","author":"Kirkpatrick","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.ackd.2010.05.007_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0002-9343(98)00244-7","article-title":"A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate","volume":"105","author":"Gilbert","year":"1998","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2010.05.007_bib9","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/AAC.40.11.2494","article-title":"Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy","volume":"40","author":"Prins","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib11","first-page":"223","article-title":"Once-daily dosing of aminoglycosides. A consensus document","volume":"35","author":"Anaizi","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1053\/j.ackd.2010.05.007_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijantimicag.2003.07.010","article-title":"Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing","volume":"23","author":"Xuan","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1053\/j.ackd.2010.05.007_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/infdis\/158.4.831","article-title":"Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model","volume":"158","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib14","series-title":"Drug Prescribing in Renal Failure","author":"Aronoff","year":"2007"},{"key":"10.1053\/j.ackd.2010.05.007_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2215\/CJN.02920707","article-title":"Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing","volume":"3","author":"Sowinski","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.05.007_bib16","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archinte.1978.03630360019012","article-title":"Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy","volume":"138","author":"Gailiunas","year":"1978","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2010.05.007_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.ki.5002295","article-title":"Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine","volume":"72","author":"Feldman","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.05.007_bib18","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1128\/AAC.41.12.2597","article-title":"Administration of aminoglycosides to hemodialysis patients immediately before dialysis: A new dosing modality","volume":"41","author":"Matsuo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2215\/CJN.01600407","article-title":"Administration of tobramycin in the beginning of the hemodialysis session: A novel intradialytic dosing regimen","volume":"2","author":"Kamel Mohamed","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.05.007_bib20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270006286902","article-title":"Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis","volume":"46","author":"Dang","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.ackd.2010.05.007_bib21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0091270006292987","article-title":"Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis","volume":"46","author":"Teigen","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.ackd.2010.05.007_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1525-139X.2008.00554.x","article-title":"Aminoglycosides in hemodialysis patients: Is the current practice of post dialysis dosing appropriate?","volume":"22","author":"O'Shea","year":"2009","journal-title":"Semin Dial"},{"key":"10.1053\/j.ackd.2010.05.007_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.mcna.2004.11.007","article-title":"Drug dosing in chronic kidney disease","volume":"89","author":"Gabardi","year":"2005","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.ackd.2010.05.007_bib24","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1128\/AAC.38.9.2101","article-title":"Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin","volume":"38","author":"Mueller","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.ajkd.2003.08.027","article-title":"Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin","volume":"42","author":"Kays","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2215\/CJN.01580407","article-title":"Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin","volume":"2","author":"How","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.05.007_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(03)00061-8","article-title":"Clinical pharmacodynamics of quinolones","volume":"17","author":"Ambrose","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1053\/j.ackd.2010.05.007_bib28","first-page":"145","article-title":"Dose adjustment of ciprofloxacin in renal failure: Reduce the dose or prolong the administration interval?","volume":"10","author":"Czock","year":"2005","journal-title":"Eur J Med Res"},{"key":"10.1053\/j.ackd.2010.05.007_bib29","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/0002-9343(92)90302-R","article-title":"Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones","volume":"92","author":"Blum","year":"1992","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2010.05.007_bib30","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insights from the society of infectious diseases pharmacists","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ackd.2010.05.007_bib31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.clinthera.2010.04.003","article-title":"Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States","volume":"32","author":"Koomanachai","year":"2010","journal-title":"Clin Ther"},{"key":"10.1053\/j.ackd.2010.05.007_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib33","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin\u2013\u2013United States","volume":"51","author":"CDC","year":"2002","journal-title":"MMWR"},{"key":"10.1053\/j.ackd.2010.05.007_bib34","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib35","unstructured":"Infectious Diseases Society of America: FDA lowers vancomycin breakpoints for Staphylococcus aureus. Available at: http:\/\/www.idsociety.org\/Content.aspx?id=11378. Accessed January 21, 2010"},{"key":"10.1053\/j.ackd.2010.05.007_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/clpt.2009.150","article-title":"Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy","volume":"86","author":"Mueller","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.ackd.2010.05.007_bib37","series-title":"Vancomycin hydrochloride (vancomycin hydrochloride for injection) [package insert]","year":"2004"},{"key":"10.1053\/j.ackd.2010.05.007_bib38","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1093\/ndt\/12.12.2647","article-title":"Vancomycin mass transfer characteristics of high-flux cellulosic dialysers","volume":"12","author":"Scott","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"10.1053\/j.ackd.2010.05.007_bib39","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib40","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01590309","article-title":"Staphylococcus aureus infections in hemodialysis: What a nephrologist should know","volume":"4","author":"Vandecasteele","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.05.007_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib42","unstructured":"Bhavnani SM, Ambrose PG, Rubino CM, et al: Toxicodynamics of daptomycin in patients with bacteremia and\/or endocarditis. Poster presented at: 46th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, September 27-30, 2006"},{"key":"10.1053\/j.ackd.2010.05.007_bib43","series-title":"Cubicin [package insert]","year":"2010"},{"key":"10.1053\/j.ackd.2010.05.007_bib44","first-page":"691A","article-title":"Daptomycin pharmacokinetics in patients treated with continuous venovenous hemodialysis [abstract]","volume":"19","author":"Vilay","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.05.007_bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ndt\/gfp655","article-title":"Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients","volume":"25","author":"Salama","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2010.05.007_bib46","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.01650309","article-title":"Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis","volume":"4","author":"Salama","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.05.007_bib47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jac\/dkp155","article-title":"Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection","volume":"64","author":"Chakraborty","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib48","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.48.8.3043-3050.2004","article-title":"Pharmacodynamics of Telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria","volume":"48","author":"Hegde","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib49","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In vivo pharmacodynamic activity of the glycopeptide dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2010.05.007_bib50","series-title":"Vibativ [package insert]","year":"2009"},{"key":"10.1053\/j.ackd.2010.05.007_bib51","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2146\/ajhp070080","article-title":"Telavancin: A novel lipoglycopeptide antimicrobial agent","volume":"64","author":"Attwood","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.ackd.2010.05.007_bib52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/039139880903201006","article-title":"Telavancin and hydroxyl propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study","volume":"32","author":"Patel","year":"2009","journal-title":"Int J Artif Organs"},{"key":"10.1053\/j.ackd.2010.05.007_bib53","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0091270008330162","article-title":"Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment","volume":"49","author":"Marbury","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.ackd.2010.05.007_bib55","doi-asserted-by":"crossref","unstructured":"Vilay AM, Shah KH, Churchwell MD, et al: Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies. Blood Purif (in press)","DOI":"10.1159\/000316685"},{"key":"10.1053\/j.ackd.2010.05.007_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ackd.2006.04.009","article-title":"Avoiding trouble down the line: The management and prevention of hemodialysis catheter-related infections","volume":"13","author":"Lok","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib57","first-page":"S1","article-title":"Clinical practice guidelines and clinical practice recommendations for 2006 updates: Hemodialysis adequacy, peritoneal dialysis adequacy and vascular access","volume":"48","author":"National Kidney Foundation (KDOQI)","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib58","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1525-139X.2008.00497.x","article-title":"Infection associated with tunneled hemodialysis catheters","volume":"21","author":"Bearthard","year":"2008","journal-title":"Semin Dial"},{"key":"10.1053\/j.ackd.2010.05.007_bib59","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/039139880803100911","article-title":"Catheter-related bacteremia in hemodialysis patients: The role of the central venous catheter in prevention and therapy","volume":"31","author":"Troidle","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1053\/j.ackd.2010.05.007_bib60","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0272-6386(01)80126-8","article-title":"Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers","volume":"37","author":"Sowinski","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"44","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0272-6386(99)70262-3","article-title":"Dialyzer-dependent changes in solute and water permeability with bleach reprocessing","volume":"33","author":"Scott","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib63","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1592\/phco.19.13.1042.31587","article-title":"The effects of peracetic acid-hydrogen peroxide reprocessing on dialyzer solute and water permeability","volume":"19","author":"Scott","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ackd.2010.05.007_bib64","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1053\/j.ackd.2007.03.004","article-title":"Drug dosing considerations in alternative hemodialysis","volume":"14","author":"Decker","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ackd.2010.05.007_bib65","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/089686080402400509","article-title":"Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis","volume":"24","author":"Yeung","year":"2004","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.ackd.2010.05.007_bib66","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1345\/aph.18152","article-title":"Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis","volume":"32","author":"Dahl","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ackd.2010.05.007_bib67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/089686089901900607","article-title":"Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis","volume":"19","author":"Brophy","year":"1999","journal-title":"Perit Dial Int"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559510000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559510000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T17:55:11Z","timestamp":1591811711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559510000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1548559510000844"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2010.05.007","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}